Abstract：
The Serum Response Factor (SRF) is a transcription factor involved in three hallmarks of cancer: the promotion of cell proliferation, cell death resistance and invasion and metastasis induction. Many studies have demonstrated a leading role in the development and progression of multiple cancer types, thus highlighting the potential of SRF as a prognostic biomarker and therapeutic target, especially for cancers with poor prognosis.
This review examines the role of SRF in several cancers in promoting cellular processes associated with cancer development and progression. SRF co-factors and signaling pathways are discussed as possible targets to inhibit SRF in a tissue and cancer-specific way. Small-molecule inhibitors of SRF, such as the CCGs series of compounds and lestaurtinib, which could be used as cancer therapeutics, are also discussed.
Targeting of SRF and its co-factors represents a promising therapeutic approach. Further understanding of the molecular mechanisms behind the action of SRF could provide a pipeline of novel molecular targets and therapeutic combinations for cancer. Basket clinical trials and the use of SRF immunohistochemistry as companion diagnostics will help testing of these new targets in patients.
This review examines the role of SRF in several cancers in promoting cellular processes associated with cancer development and progression. SRF co-factors and signaling pathways are discussed as possible targets to inhibit SRF in a tissue and cancer-specific way. Small-molecule inhibitors of SRF, such as the CCGs series of compounds and lestaurtinib, which could be used as cancer therapeutics, are also discussed.
Targeting of SRF and its co-factors represents a promising therapeutic approach. Further understanding of the molecular mechanisms behind the action of SRF could provide a pipeline of novel molecular targets and therapeutic combinations for cancer. Basket clinical trials and the use of SRF immunohistochemistry as companion diagnostics will help testing of these new targets in patients.
摘要：
血清反应因子（SRF）是参与癌症的三个标志的转录因子：促进细胞增殖，细胞死亡抗性和侵袭转移诱导。许多研究表明，在多种癌症类型的发展和进展中起主导作用，因此突出了SRF作为预后生物标志物和治疗靶标的潜力，尤其是预后不良的癌症。
这篇综述研究了SRF在几种癌症中促进与癌症发展和进展相关的细胞过程中的作用。讨论了SRF辅因子和信号通路作为以组织和癌症特异性方式抑制SRF的可能靶标。SRF的小分子抑制剂，如CCGs系列化合物和列妥替尼，可以用作癌症治疗，也讨论了。
靶向SRF及其辅因子代表了一种有希望的治疗方法。对SRF作用背后的分子机制的进一步理解可以为癌症提供新的分子靶标和治疗组合的管道。篮子临床试验和使用SRF免疫组织化学作为伴随诊断将有助于在患者中测试这些新目标。
这篇综述研究了SRF在几种癌症中促进与癌症发展和进展相关的细胞过程中的作用。讨论了SRF辅因子和信号通路作为以组织和癌症特异性方式抑制SRF的可能靶标。SRF的小分子抑制剂，如CCGs系列化合物和列妥替尼，可以用作癌症治疗，也讨论了。
靶向SRF及其辅因子代表了一种有希望的治疗方法。对SRF作用背后的分子机制的进一步理解可以为癌症提供新的分子靶标和治疗组合的管道。篮子临床试验和使用SRF免疫组织化学作为伴随诊断将有助于在患者中测试这些新目标。
